PEP-Therapy's peptides block specific protein-protein interactions
PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins.
The company's fusion peptides comprise an optimized cell-penetrating peptide that shuttles a short interfering peptide into the cell.
The shuttle is a 12-amino-acid peptide derived from an enzyme in a cattle parasite. The biotech modified the peptide with point mutations to prevent degradation by proteases, which in turn improves in vivo stability and cellular